Treatment of the chemotherapy induced hepatotoxicity

Ivanikov, Igor O.; Виноградова, Н. Н.; Krashenkov, O. P.; Kotselapova, E.Yu.; Grigorieva, Yu.V.; Myasnikova, E.V.; Pikunova, I.N.

doi:10.17116/dokgastro202090417

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach is logical in the treatment of aggressive metastatic cancers, as it is necessary to obtain maximum bioavailability from each dose of the drug. To date, intravenous chemotherapy has been the most studied and used in the treatment of malignant neoplasms while causing a wide spectrum of side effects associated with high drug toxicity [2,[6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Implantation of In Situ Gelling Systems for the Delivery of Chemotherapeutic Agents

Bakhrushina,

Mikhel,

Buraya

et al. 2024

Gels

View full text Add to dashboard Cite

Implantation is a modern method of administering chemotherapeutic agents, with a highly targeted effect and better patient tolerance due to the low frequency of administration. Implants are capable of controlled release, which makes them a viable alternative to infusional chemotherapy, allowing patients to enjoy a better quality of life without the need for prolonged hospitalization. Compared to subcutaneous implantation, intratumoral implantation has a number of significant advantages in terms of targeting and side effects, but this area of chemotherapy is still poorly understood in terms of clinical trials. At the same time, there are more known developments of drugs in the form of implants and injections for intratumoral administration. The disadvantages of classical intratumoral implants are the need for surgical intervention to install the system and the increased risk of tumor rupture noted by some specialists. The new generation of implants are in situ implants—systems formed in the tumor due to a phase transition (sol–gel transition) under the influence of various stimuli. Among this systems some are highly selective for a certain type of malignant neoplasm. Such systems are injected and have all the advantages of intratumoral injections, but due to the phase transition occurring in situ, they form depot forms that allow the long-term release of chemotherapeutic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Implantation of In Situ Gelling Systems for the Delivery of Chemotherapeutic Agents

Bakhrushina,

Mikhel,

Buraya

et al. 2024

Gels

View full text Add to dashboard Cite

show abstract

Toxic complications of high doses of treîsulfan in children: experience of the N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

Aliev,

Machneva,

Kostareva

et al. 2023

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) is a treatment method for a number of severe malignant and non-tumor diseases. Autologous (auto) and allogeneic (allo) HSCT improves outcomes in patients with solid and hematological malignancies. The toxicity of conditioning regimens before HSCT is often a limiting factor for successful transplant outcomes. The most common manifestations of visceral and tissue toxicity are epithelial (dermatological and mucosal) toxicity, hepatotoxicity, and neurotoxicity. Reducing the incidence of toxic complications of preparative regimens preceding HSCT is the optimization of accompanying therapy, and and individualized selection of doses of chemotherapy. In our study, among 119 HSCT cases performed in 2021–2022, treosulfan-containing preparative regimens were used. Dermatological toxicity was diagnosed in 80.0 %, mucositis – in 100 %, hepatotoxicity – in 18.5 % of observations, no neurological toxicity was recorded.

show abstract

Evaluation of the efficiency of the hepatoprotector glucuronate in toxic hepatitis of various etiology

Akalaev,

Khadjibaev,

Stopnitskiy

et al. 2024

Vestn. anesteziol. reanimatol.

View full text Add to dashboard Cite

The objective was to study the effectiveness of the use of hepatoprotector glucuronate at the early stage of intensive therapy of toxic hepatitis of various etiologies.Materials and methods. We studied 120 patients with toxic hepatitis who were treated at the Republican research center for emergency medicine in 2022–2023. The study was carried out in two groups of patients. Group I – 60 patients admitted in 2023, who, in addition to traditional therapy, received a complex hepatoprotector glucuronate (Jetepar®)*. Group II (comparison group) – 60 patients who applied in 2022 and received only traditional therapy. Biochemical blood parameters were studied upon admission and over time on day 5. The severity of intellectual impairment was assessed using cognitive scales and the Reitan test on days 2 and 5 from the start of treatment.Results. Upon admission, both groups showed signs of toxic liver damage. In dynamics by the 5th day in patients of group I, there was a decrease in ALT by 63.7%, AST by 66.4%, alkaline phosphatase by 54.2% from the initial values, which was 3.9 and 2.6, 2. 1 lower than in the comparison group. The level of free ammonia in patients of group I on the 5th day decreased by 52%, and lactate by 57% from the initial level, almost to the physiological norm, while in the comparison group (II) only by 24.8% and 38.1%, which was 2.2 and 1.5 times worse than in the main group. Screening of the level of intelligence using two cognitive scales and the Reitan test showed that in patients in the comparison group, cognitive function indicators on the 5th day were 1.4, 1.5 and 1.2 times lower than in the main group.Conclusion. The use of the hepatoprotector glucuronate improves liver parameters and cognitive functions in patients with toxic hepatitis.

show abstract

Treatment of the chemotherapy induced hepatotoxicity

Cited by 3 publications

References 4 publications

Implantation of In Situ Gelling Systems for the Delivery of Chemotherapeutic Agents

Implantation of In Situ Gelling Systems for the Delivery of Chemotherapeutic Agents

Toxic complications of high doses of treîsulfan in children: experience of the N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

Evaluation of the efficiency of the hepatoprotector glucuronate in toxic hepatitis of various etiology

Contact Info

Product

Resources

About